|
US2018236035A1
|
|
Protein therapy for treatment of retinal diseases
|
|
WO2018002811A1
|
|
Compression apparatuses for positioning and immobilizing a patient and related methods
|
|
WO2017087881A1
|
|
Apparatuses for detecting and/or destroying abnormal tissue, such as cancer tissue, and related methods
|
|
US2018250053A1
|
|
Line Passing Devices and Related Kits and Methods
|
|
US2018177526A1
|
|
Vascular graft securement apparatuses and related kits and methods
|
|
AU2015201485A1
|
|
Devices, apparatuses, and methods for tissue suspension
|
|
US2015159999A1
|
|
Clearance check devices, systems, and methods
|
|
WO2015026956A1
|
|
Surgical apparatuses for coupling elongated members to endoscopes, and related methods
|
|
US2014286914A1
|
|
Protein therapy for treatment of retinal diseases
|
|
AU2014201901A1
|
|
Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
|
|
US2015110789A1
|
|
Bispecific scFv immunofusion (BIf)
|
|
AU2013203576A1
|
|
Devices, apparatuses, and methods for tissue suspension
|
|
WO2012135848A2
|
|
Melatonin-based treatment and diagnosis of bile duct disease
|
|
WO2012112869A2
|
|
Targeted cancer therapy using ets transcriptional inhibitors
|
|
WO2012097255A2
|
|
Therapeutic effect of heat shock proteins in preventing amylin aggregation in type 2 diabetes mellitus
|
|
WO2012145037A1
|
|
Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease
|
|
EP2637692A2
|
|
Antibodies to tumor endothelial marker 8
|
|
WO2012061015A2
|
|
L-citrulline supplementation during arginine depletion therapy with arginase
|
|
WO2011112838A2
|
|
Composition and method for treatment of vascular hyperpermeability
|
|
US2011207154A1
|
|
Method for determination of marinobufagenin levels and compounds employable in such method
|
